Droxidopa
Droxidopa is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Droxidopa; Generic name: DROXIDOPA; Manufacturer: ScieGen Pharmaceuticals Inc.
| Brand name | Droxidopa |
|---|---|
| Generic name | DROXIDOPA |
| Manufacturer | ScieGen Pharmaceuticals Inc |
| Used for | 1 INDICATIONS AND USAGE Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. Droxidopa Capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you ar |
| Dosage | 2 DOSAGE AND ADMINISTRATION Starting dose is 100 mg three times during the day ( 2.1 ) Titrate by 100 mg three times daily, up to a maximum dose of 600 mg three times daily ( 2.1 ) Take consistently with or without food ( 2.1 ) To reduce the potential for supine hypertension, elevate the head of the bed and give the last dose at least 3 hours prior to bedtime ( 2.1 ) Take Droxidopa capsule whole ( 2.1 ) 2.1 Dosing Information The recommended starting dose of Droxidopa capsules is 100 mg, taken o |
| Warnings | WARNING: SUPINE HYPERTENSION Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue Droxidopa [ see Warnings and Precautions ( 5.1 ) ]. WARNING: SUPINE HYPERTENSION See full prescribing information for complete boxed warning. |
| Active ingredient(s) | DROXIDOPA |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10b02d98-ebb8-4152-bd56-3402417fbf79 |